ArticleMolecules and cells2018
Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance.
Article in Molecules and cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 53 citations in OpenAlex.
- Metabolic obesity phenotypic stability, dynamic transformation and risk of hypertension: a 10-year prospective cohort study in southwest China.International journal of obesity (2005) · 2026Article
- Research Progress on Chemical Components ofMolecules (Basel, Switzerland) · 2025Review
- Therapeutic potential and mechanistic insights of astragaloside IV in the treatment of arrhythmia: a comprehensive review.Frontiers in pharmacology · 2025Review
- Research progress on the mechanistic impact of single-nucleotide polymorphisms and dietary pattern interactions on overweight and obesity in Chinese adults: a narrative review.Frontiers in nutrition · 2025Review
- A Review of the Mechanisms of Astragaloside IV and Berberine in Vascular Dysfunction Associated with Obesity and Diabetes.Drug design, development and therapy · 2025Review
- Advance on Chinese Medicine for Hypertensive Renal Damage: Focus on the Complex Molecular Mechanisms.Chinese journal of integrative medicine · 2024Review
- Astragali Radix: comprehensive review of its botany, phytochemistry, pharmacology and clinical application.Archives of pharmacal research · 2024Review
- Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.Heliyon · 2024Article
- Effects of astragaloside IV on glucocorticoid-induced avascular necrosis of the femoral head via regulating Akt-related pathways.Cell proliferation · 2023Article
- Could Cyclosiversioside F Serve as a Dietary Supplement to Prevent Obesity and Relevant Disorders?International journal of molecular sciences · 2023Review
- Epicardial Adipose Tissue-Derived Leptin Promotes Myocardial Injury in Metabolic Syndrome Rats Through PKC/NADPH Oxidase/ROS Pathway.Journal of the American Heart Association · 2023Article
- Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.Journal of cellular and molecular medicine · 2023Article
- Exploration of the mechanism by which Huangqi Guizhi Wuwu decoction inhibits Lps-induced inflammation by regulating macrophage polarization based on network pharmacology.BMC complementary medicine and therapies · 2023Article
- Experimental animal models of chronic inflammation.Current research in immunology · 2023Review
- Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats.Molecular medicine reports · 2023Article
- Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments.Applied biochemistry and biotechnology · 2022Article
- Recent evidence in support of traditional chinese medicine to restore normal leptin function in simple obesity.Heliyon · 2022Review
- Metabolically healthy versus unhealthy obese phenotypes in relation to hypertension incidence; a prospective cohort study.BMC cardiovascular disorders · 2022Article
- Chemical Profiles and Antiobesity Effect of a Mixture ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Protective Effects of Astragaloside IV on Uric Acid-Induced PancreaticEvidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade pro-inflammatory state and leptin resistance are important underlying mechanisms that contribute to obesity-associated hypertension. We tested the hypothesis that Astragaloside IV (As IV), known to counteract obesity and hypertension, could prevent obesity-associated hypertension by inhibiting pro-inflammatory reaction and leptin resistance. High-fat diet (HFD) induced obese rats were randomly assigned to three groups: the HFD control group (HF con group), As IV group, and the As IV + α-bungaratoxin (α-BGT) group (As IV+α-BGT group). As IV (20 mg·Kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.